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Tibial muscular dystrophy (TMD) is an autosomal dominant late-onset distal myopathy linked to chromosome
2q31. The linked region includes the giant TTN gene, which encodes the central sarcomeric protein, titin. We have
previously shown a secondary calpain-3 defect to be associated with TMD, which further underscored that titin
is the candidate. We now report the first mutations in TTN to cause a human skeletal-muscle disease, TMD. In
Mex6, the last exon of TTN, a unique 11-bp deletion/insertion mutation, changing four amino acid residues,
completely cosegregated with all tested 81 Finnish patients with TMD in 12 unrelated families. The mutation was
not found in 216 Finnish control samples. In a French family with TMD, a LeurPro mutation at position 293,357
in Mex6 was discovered. Mex6 is adjacent to the known calpain-3 binding site Mex5 of M-line titin. Immuno-
histochemical analysis using two exon-specific antibodies directed to the M-line region of titin demonstrated the
specific loss of carboxy-terminal titin epitopes in the TMD muscle samples that we studied, thus implicating a
functional defect of the M-line titin in the genesis of the TMD disease phenotype.
Introduction
Tibial muscular dystrophy (TMD [MIM 600334]) is an
autosomal dominant late-onset distal myopathy that was
first described, in Finnish patients, by Udd et al. (1991,
1993). In TMD, weakness and atrophy are usually con-
fined to the anterior compartment of the lower leg—in
particular, the tibialis anterior muscle. Clinical symptoms
usually occur at age 35–45 years—or much later. Car-
diomyopathy has not been diagnosed in patients with
TMD, and there is no facial-muscle involvement (Udd et
al. 1992, 1993).
We have assigned linkage of TMD to a 1-cM region
on chromosome 2q31, between markers D2S2173 and
D2S2310, in the Finnish families with TMD (Haravuori
et al. 1998). All Finnish patients with TMD carry a com-
mon core haplotype for the linked markers, which in-
dicates that there is a single ancestral founder mutation
responsible for TMD in the Finnish population. Three
patients with a more severe childhood-onset limb-girdle
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muscular dystrophy (LGMD) phenotype were found to
be homozygous for the TMD haplotype (Haravuori et
al. 1998). The prevalence of TMD is 16/100,000, which
makes it one of the most common myopathies in Fin-
land. Linkage to this same chromosome 2q31 locus has
also been confirmed in a French family with TMD that
showed another haplotype for the linked markers (de
Seze et al. 1998).
The major positional and functional candidate gene at
the TMD locus is the TTN gene, encoding the giant mus-
cle protein titin (formerly named “connectin”) (Haravuo-
ri et al. 2001). The entire coding region of titin consists
of 363 exons, which encodes 38,138 amino acid residues
(4,200 kD). The size of skeletal-muscle titin is 3,700 kD,
and the physical length in vivo is 2 mm (Bang et al. 2001).
Titin has mechanical, developmental, and regulatory
roles in striated muscles. It stretches over the length of
one-half of the sarcomere, from the Z disk to the M line
(Labeit and Kolmerer 1995). Titin has many properties
that make it a highly interesting candidate for TMD.One
of the main functions of titin is to keep the contractile
elements of the sarcomere in place, and it is responsible
for muscle elasticity. Titin also provides multiple ligand
binding sites for a large number of other muscle proteins,
including the muscle-specific protease calpain-3, a-ac-
tinin, myosin, myomesin, and telethonin (Labeit et al.
1992; Trinick 1994; Freiburg and Gautel 1996; Young
et al. 1998). Z-disk titin contains telethonin/T-cap bind-
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Figure 1 Structure of skeletal-muscle titin. The location of calpain-3 binding sites and the site of Mex6 mutations are indicated. Lower
schematic picture shows the 3′/C-terminal modular structure of titin, providing a more detailed illustration of ligand and antibody binding sites.
ing sites and multiple a-actinin binding sites (Sorimachi
et al. 1997; Gregorio et al. 1998; Mues et al. 1998), and
it interacts indirectly with myotilin via a-actinin (Sal-
mikangas et al. 1999). Mutations in calpain-3, myosin,
telethonin, and myotilin are known to cause other mus-
cular dystrophies. Close to its C-terminus, titin has a Ser/
Thr–kinase domain, homologous to myosin light-chain
kinases (Labeit et al. 1992), which potentially phospho-
rylates telethonin during early myocyte differentiation
(Mayans et al. 1998) (see fig. 1).
TTN has several sites for alternative splicing, causing
isoforms of different lengths to appear in different mus-
cles (Bang et al. 2001). I-band isoforms have been ob-
served to be longer in skeletal (3,700 kD) than in cardiac
(2,970–3,300 kD) muscle, whereas, in the Z disk, car-
diac-muscle titins contain more repeat motifs than do
skeletal-muscle titins (Gautel et al. 1996; Sorimachi et al.
1997). Interacting with obscurin, a C-terminally trun-
cated 700-kD isoform of titin is expressed in cardiac
muscle (Bang et al. 2001). The M-line region of titin is
also differentially expressed, and two different splice iso-
forms have been identified: Mex5 and Mex5 (Labeit
and Kolmerer 1995; Kolmerer et al. 1996; Sorimachi et
al. 1997). On the ultrastructural level, both the carboxy-
terminal Mex6 titin epitope and the catalytic titin kinase
domain have been localized within the periphery of the
M-line lattice (Obermann et al. 1997). Therefore, the
Mex5/Mex6 titin epitopes, the catalytic titin kinase do-
main, and the p94 and muscle-specific ring finger–1
(MURF-1) proteins that are bound to this region of titin
may form a signaling complex (Sorimachi et al. 1997;
Centner et al. 2001). The occurrence of several different
titin isoforms may be relevant for the selective involve-
ment of muscles in anatomically restricted myopathies
(Sorimachi et al. 1997). Recently, autosomal dominant
dilated cardiomyopathy was shown to be associatedwith
A-band TTN mutations in exon 326, which cause a
frameshift, and with a mutation in the Z-disk TTN (Siu
et al. 1999; Gerull et al. 2002).
Autosomal recessive LGMD2A is caused by mu-
tations in the gene, on chromosome 15, that encodes
muscle-specific calpain-3 (Richard et al. 1995). Myo-
nuclear apoptosis and perturbation of the IkBa/nu-
clear factor–kB pathway have been associated with
absence of functional calpain-3 in LGMD2A muscle
(Baghdiguian et al. 1999). Because of the similarities
between LGMD2A and the LGMD phenotype that is
associated with homozygous state of TMD, we pre-
viously screened for—and found—secondary calpain-
3 deficiency in TMD (Haravuori et al. 2001). Myonu-
clear apoptosis and altered IkBa/nuclear factor–kB
pathway were also observed (Haravuori et al. 2001).
In mice, a spontaneous mutation in the proximal part
of chromosome 2, a region syntenic to human chro-
mosome 2q31, causes muscular dystrophywithmyositis
(MDM) (Siracusa et al. 1990; Mu¨ller-Seitz et al. 1993).
The mouse titin gene (Ttn) colocalizes with this disease
locus, and a deletion of the N2-A–line calpain-3 binding
site of mouse titin was recently reported to cause MDM
(Garvey et al. 2002), a result that is consistent with our
previous demonstration of secondary calpain-3 defi-
ciency in the MDM mouse (Haravuori et al. 2001).
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Titin has at least two binding sites for calpain-3, and
it has been suggested that it stabilizes calpain-3 from
autolytic degradation (see fig. 1). The three immuno-
globulin (Ig) repeats (exons I81–I83) on the N2-A line
of I-band titin constitute one binding site, and the other
is in M-line titin (Sorimachi et al. 1995).
The complete 294-kb sequence of TTN is organized
into 363 exons (GenBank accession numberAJ277892).
All exons originally known to be expressed in human
soleus skeletal muscle (348 of a total of 363) of TTN
were sequenced. Samples sequenced were from two Finn-
ish heterozygous patients with TMD, three unrelated
French heterozygous patients with TMD, one Finnish
homozygous patient with TMD, and unaffected control
individuals.
Material and Methods
Patient Material
Patient material was obtained from the four Finnish
families (with 68 affected and 70 healthy members
total) and one French family (with 3 affected and 4
healthy members) that were included in the previous
linkage studies (de Seze et al. 1998; Haravuori et al.
1998). In the present study, we included 13 patients,
from eight unrelated families, who have not been de-
scribed elsewhere, and their 6 healthy relatives. DNA
extracted from blood lymphocytes and the muscle bi-
opsy samples for immunohistochemical analyses were
available from previous studies (Haravuori et al. 1998,
2001). All the samples were obtained from informed
and consenting individuals. The study protocol was ap-
proved by the ethical board of Vasa Central Hospital.
Sequencing
The entire TTN coding region as known at the time,
including 348 of 363 exons, was sequenced using patient
and control DNA. Ninety-three unaffected population
control individuals from France were screened, for exon
Mex6 mutations, by sequencing. The titin sequenceswere
amplified by PCR and were run in agarose gels to confirm
fragment size and specificity of the PCR. PCR products
were purified by Qiagen columns before sequencing. The
sense and antisense strands were sequenced using a Big-
Dye Terminator Cycle sequencing Ready Reaction DNA
kit (Applied Biosystems), according to the manufacturer’s
instructions (Chadwick et al. 1996). Extension products
were purified, and the samples were run on an ABI 377
sequencer (Perkin Elmer). Sequencher 3.1.1 software was
used for analysis of the sequences.
SSCP Analysis
SSCP analysis, as described by Vidal-Puig andMoller
(1994), was used to screen patients and control indi-
viduals for the putative TMD-causing mutation in exon
Mex6 of TTN. PCRs were performed using a primer
pair designed for a 184-bp fragment, including the 11-
bp mutated area, of the Mex6 exon. Primers used were
as follows: A (CAGCATTGATGAAGGCAAAG) and
B (TCCACCATCTTGTTTCTGTACG). DNA samples
from 78 heterozygous and 3 homozygous patients with
TMD, as well as from 76 healthy relatives, were tested.
Two hundred sixteen unaffected population control in-
dividuals from Finland (56 from the National Public
Health Institute and 160 from the Finnish Red Cross)
were screened for the mutation. The PCR products were
mixed with loading buffer, were denatured at 95C for
5 min, and were placed on ice. Gel electrophoresis was
performed at 3 W for 15 h in a 0.5 # MDE polyacryl-
amide gel (BioWhittaker Molecular Applications) in 0.6
# Tris-borate–EDTA buffer. The gels were stained using
the silver staining method and were fixed and dried (Vi-
dal-Puig and Moller 1994; Donner et al. 2002). The gels
were scanned at 300 dpi with an Agfa Snapscan 1236s
image scanner. Adobe Photoshop, version 5.5, was used
for image enhancement and detection of the bands. The
sequences containing the mutation showed aberrant mi-
gration and, by this method, proved to be very clearly
distinguishable from the wild-type sequence.
Primers
More than 500 primers for PCR amplification and
sequencing were designed using the Primer3 software
(developed, at the Whitehead Institute for Biomedical
Research, by Steve Rozen and Helen J. Skaletsky; avail-
able at the Primer3 Software Distribution Web site).
Primer sequences are available on request.
RNA Extractions and RT-PCRs
Total RNA was extracted with Purescript RNA Isola-
tion Kit (Gentra) from muscle biopsy samples that were
surgically obtained, were immediately frozen in liquid ni-
trogen, and were stored at80C. cDNAwas synthesized
by use of 200 ng total RNA as template, with 200 U
M-MLV reverse transcriptase (Promega), 20 U RNAse
inhibitor (Rnasin; Promega), 0.8 mM specific primer, 0.6
mM deoxyribonucleoside triphosphate, and buffer in a
total volume of 25 ml.
Immunohistochemical Methods
Muscle biopsy samples from one homozygous patient
with TMD, from three heterozygous patients withTMD,
and from an unaffected control individual were analyzed.
Standard immunohistochemistry and immunofluores-
cence protocols were used on unfixed frozen 6-mm
longitudinal muscle sections. For obtainment of exon-
specific titin antibodies, the Ig/Fn3 domains A169/A170
(corresponding to the Mex1 exon and containing the
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Table 1
New TTN Sequence Differences between Finnish Patients
with TMD and Control Individuals
Exon (Position) in TTN Mutation Effect
4 of PEVK66 (162,097) TrC Close to splice site
A45 (233,784) ACTrATT ThrrIle
A149 (274,193) AGTrGGT SerrGly
A166 (283,464) GTTrATT ValrIle
Mex6 (293,268–293,280) 11-bp change 4-amino-acid change
Mex6 UTR (293,564) A insertion Ins in 8 A stretch
NOTE.—Only changes that cosegregated with TMD, either in exons
causing an amino acid change or at exon/intron borders, are listed. The
changes in A45 and A149 cause the exchange from neutral polar amino
acid to neutral nonpolar amino acid. The insertion at position 293,564
is outside the translated region, in the last exon. (For previously reported
polymorphisms, see Haravuori et al. 2001.)
MURF-1 binding site) and the Ig domains M8/M9 (cor-
responding toMex3/Mex4)were expressed inEscherichia
coli essentially as described elsewhere (Gregorio et al.
1998). Rabbit polyclonal antibodies were raised to the
purified antigens, and obtained antisera were affinity pu-
rified (Biogenes). Both affinity-purified polyclonal anti-
bodies were used at 1:200 dilutions. The monoclonal
anti-myomesin B4 (Grove et al. 1984)was used at dilution
1:10. A Ventana Nexes automated immunostainer (Ven-
tana Medical Systems) was employed for immunohisto-
chemistry, by the avidin-biotin–complexmethod followed
by 3,3′-diaminobenzidine (DAB) detection. Immunofluo-
rescent detection was manually performed using fluores-
cein isothiocyanate (FITC)–conjugated secondary anti-
body (DAKO 0205; DAKO A/S). A control section from
healthy muscle was placed on every slide.
Results
More than 20 SNPs were detected in TTN in patients
with TMD (for previously reported polymorphisms, see
Haravuori et al. 2001). None of these SNPs were frame-
shift mutations, and only five of them either were close
to intron/exon borders or, in exons, changed an amino
acid residue; the amino acid charge was not changed in
these cases (see table 1). In the Finnish TMD samples, a
unique mutation was identified in Mex6, the 363rd and
last exon of TTN. Mex6 of TTN encodes an Ig domain
that, in situ, is localized at the periphery of the M-line
lattice. Mex6, together with Mex5, is in the region de-
termining the calpain-3 binding site of M-line titin. The
mutation consists of an 11-bp change, AAGTAACA-
TGGrTGAAAGAAAAA, at position 293,269–293,279
in the TTN sequence. The mutation changes four amino
acids—GAArGTG (GlurVal), GTArAAA (ValrLys),
ACArGAA (ThrrGlu), TGGrAAA (TrprLys) (see fig.
2)—close to the C-terminal end of the titin protein but
does not cause a frameshift or a stop codon. Each of the
four amino acids is changed to an amino acid of another
charge, and the overall charge is changed from acidic
(1) to basic (1). Neither the particular Mex6 DNA
sequence variant nor the resultant amino acid sequence
of this variant part (underlined) of titin, DEGKVLTV-
ACAFTGEPTPVKEKCGGR, has been reported else-
where, as tested by performance of a nucleotide sequence
and a protein search (see the National Center for Bio-
technology’s BLASTWeb site) (Altschul et al. 1997). The
affected titin protein segment is relatively well conserved
in humans, pigs, mice, and chickens. There are some
very small differences in mouse and chicken protein se-
quences, compared to human titin.
The 11-bp mutation was easily detected by SSCP
analysis (Vidal-Puig and Moller 1994) (see fig. 2). SSCP
studies showed that this mutation did not occur in the
216 Finnish unaffected population control individuals
who were tested. When a total of 78 TMD heterozy-
gotes, 3 TMD homozygotes, and 76 healthy first-degree
relatives were tested, the mutation showed cosegrega-
tion with TMD in 12 unrelated pedigrees, in agreement
with full penetrance. One family was an exception: three
offspring aged 50–55 years did show the mutation with-
out clinically manifesting the disease. However, in this
family, the transmitting affected parent in the older gen-
eration had very late onset of symptoms, at 65 years.
These three individuals were followed up for detection
of exceptional late manifestation. All four families in
the previous linkage studies were included, as well as
eight new unrelated families.
SSCP analysis for this Mex6 region on DNA samples
from the chromosome 2q31–linked French family did not
show any aberrant bands. However, sequencing samples
from the affected persons in this family revealed another
potential mutation in Mex6 at position 293,357. This
mutation changed CTG to CCG (LeurPro) (see fig. 3).
Both amino acids are neutral hydrophobic. Themutation
was detected in three affected individuals and was not
present in four unaffected individuals from the same fam-
ily. The mutation was not present in the 93 French un-
affected population control samples (186 alleles), as an-
alyzed by sequencing. In addition, the mutation was not
found in major SNP databases (see the Web sites dbSNP
Home Page, SNP Consortium Ltd., and JNSPs Home).
We performed RT-PCR and sequenced the Mex5/
Mex6 RNA from biopsy samples of affected tibialis an-
terior muscle from a Finnish heterozygous patient with
TMD. The results showed that the Mex5/Mex6 cDNA
sequence is indeed heterologous and that both wild-type
and mutant RNAs are expressed in the affected muscle.
The sequences were in frame, indicating that the mu-
tation does not affect the splicing of these exons.
Immunohistochemical analyses of muscle biopsy
samples that were homozygous for the Finnish mu-
tation indicated loss of the M8/M9 titin epitopes,
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Figure 2 The TMD-associated 11-bp mutation at positions 293,268–293,280 in exon Mex6 of TTN. A, Nucleotide sequence with
borders of mutated area indicated by arrows. B, SSCP analysis of exon Mex6 of TTN, including the associated mutation, from patients
with TMD and unaffected control individuals. The migration of PCR products matches the haplotypes and phenotypes of the patients.
Bands indicating the mutation are marked by arrows. Samples are denoted “1”–“16.” w/wpWild-type sequence from an unaffected control
individual; w/m p TMD heterozygote; m/m p TMD homozygote; L p 100-bp DNA ladder.
Figure 3 The French TMD-associated base substitution
CTGrCCG at position 293,357, causing a LeurPro change in
exon Mex6 of TTN. Nucleotide sequence with the mutation in-
dicated by an arrow. w/w p Wild-type sequence from healthy
relative; w/m p heterozygous affected relative.
which are encoded by the Mex3/Mex4 exons, when
either DAB or FITC detection methods were used.
The loss of C-terminal titin epitopes appeared to be
specific, since TMD heterozygotes and an unaffected
control individual showed normal cross-striated sar-
comeric M-line–specific labeling when this antibody
was used (see fig. 4). Interestingly, the nearby A169/
A170 titin epitopes could be detected in biopsy sam-
ples from both homozygous and heterozygous pa-
tients with the Finnish mutation, as well as in un-
affected control individuals (see fig. 4).
Myomesin is a titin ligand relevant to the structure
of the M line in the sarcomere (Grove et al. 1984).
Immunohistochemistry showed normal expression of
myomesin in muscle from homozygous and hetero-
zygous patients with TMD (data not shown), consis-
tent with unaltered titin binding with myomesin in the
M4 domain upstream from the M8/M9 titin epitopes
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Figure 4 Muscle sections from an unaffected control individual (A), from a heterozygous patient with TMD (B), and from a homozygous
patient with TMD and LGMD (C), immunostained with titin M8/M9 antibody, and sections from an unaffected control individual (D), from
a heterozygous patient with TMD (E), and from a homozygous patient with TMD and LGMD (F), immunostained with titin A169/A170
antibody and detected by FITC.
(Obermann et al. 1997). In conclusion, our immuno-
histochemical data suggest the specific loss of titin epi-
topes C terminally of M4. This localized titin defect
appears to be compatible with the assembly of normal
sarcomeric ultrastructures in TMD (Udd et al. 1993).
Discussion
Our recent linkage studies have suggested that TTN is a
promising candidate gene for TMD—although, because
of the giant coding size of titin, no mutations could be
identified so far. Here, we describe two sequence altera-
tions in patients with TMD. We identified a complex 11-
bp mutation in the large Finnish population with TMD
and a 1-bp exchange in a French family with TMD, and
both of these mutations were localized in Mex6 (exon
363 in TTN [GenBank accession number AJ277892]).
The 11-bp Mex6 mutation represents a very unusual
type of mutation and causes, on the protein level, four
amino acid exchanges within the conserved hydrophobic
core of the M10 domain of M-line titin. It is complex
but not an inversion, and it does not seem to have orig-
inated from a secondary loop in the area. The mutation
could have originated from a recombination. The same
sequence, among three other locations, was found within
an intron that is located (using the “old numbering”)
between the A-band exons 246 (Fn3) and 247 (Ig) in the
wild-type TTN gene, 87,204 bp upstream from the mu-
tated site in Mex6. One of the four changed amino acids,
the tryptophan, is mutated into a charged lysine. The
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tryptophan residue is generally conserved in all Ig repeats
of titin and is known to be crucially important for sta-
bilization of the hydrophobic core of the Ig b-barrel fold
(Improta et al. 1996). In the French family, the mutation
at position 293,357 in Mex6 changed CTG to CCG
(LeurPro). Both amino acids are neutral hydrophobic.
Since proline differs from leucine because of its circular
structure, it may introduce a kink and cause significant
conformational change ofM-line titin structure. Themu-
tation cosegregated with the disease in the family and
was not seen in 93 French unaffected population control
samples (186 alleles), suggesting that this base exchange
is not merely a polymorphism but could indeed be related
to the disease. Similarly, the 11-bp exchange cosegregated
with the disease in the Finnish families and was absent
from 200 Finnish control chromosomes. The finding of
two independent mutations in the same exon, Mex6, in
different families with TMD further strengthens the ar-
gument that these mutations really are the cause of TMD.
Both mutant and wild-type titin RNAs are transcribed
in muscle from heterozygous patients with TMD, as
shown by RT-PCR and sequencing in the affected mus-
cles. The sequences of the heterologous cDNA were in
frame, indicating that the mutation does not affect the
splicing of the exonsMex5 andMex6. It is in accordance
with our immunofluorescence data that the mutant titin
protein is present in the muscle from the homozygous
patient with TMD, suggesting that the mutant titin is
normally translated and incorporated into themyofibril.
The lack of epitope recognition by the M-line M8/M9
antibody and the normal labeling of TMD homozygote
muscle with the antibody A169/A170, together with the
normalmyomesin expression, indicate that the titin struc-
ture may be intact up to the level of Mex2 and may be
conformationally disrupted in the Mex3–Mex6 region.
This part of titin is located within the periphery of the
M-line lattice. Interestingly, several protein-protein–in-
teraction sites are localized to this region, which could
be involved in myofibrillar signaling—namely, the titin
kinase domain (Labeit et al. 1992; Mayans et al. 1998),
p94/CAPN3 (Sorimachi et al. 1995), and MURF-1
(Bodine et al. 2001; Centner et al. 2001). Therefore, it
remains to be seen if the disruption of theM-line portion
of titin could be involved in the perturbation of titin-
based myofibrillar signaling. Defective calpain-3 regu-
lation caused by M-line titin mutations could be one
part of the mechanism. The facts thatMex6 is expressed
in heart-muscle titin and that TMD shows no cardio-
myopathy are compatible with defective titin–calpain-
3 interaction. Calpain-3 is not expressed inmature heart
muscle (Fougerousse et al. 2000). Variable proportions
of Mex5 and Mex5 isoforms in different muscles
may be responsible for selective muscle involvement.
In addition, still-unknown interactions disturbed by
the mutations in M-line titin are indicated.
Defective titin–calpain-3 interaction cannot explain
all aspects of the disease mechanism. In primary cal-
painopathy, LGMD2A, in which there is no functional
calpain-3 in the muscle, all muscles are not equally
affected, which indicates that other molecules interact
and modify the phenotype of individual muscles (Far-
deau et al. 1996). Our previous studies showed severe
reduction of calpain-3 in homozygous TMD muscle
and in the MDM mouse (Haravuori et al. 2001). In the
recent report of the MDM mutation, Garvey et al.
(2002) confirmed a decrease of calpain-3 in muscle from
a 4-wk-old MDM mouse. The phenotype in mice with
targeted calpain-3 mutation is less severe than in the
MDM mouse (Richard et al. 2000), and the phenotype
in homozygous TMD, with small amounts of calpain-
3 left in the muscle, is as severe as in LGMD2A. This
indicates that other unknown molecular mechanisms
are also disrupted by the TMD and MDM mutations
in the calpain-3 binding regions.
Functional genomics and the use of the natural animal
model, the MDM mouse, will be needed for a better
understanding of the titin–calpain-3 interaction, both
at the N2-A line and at the M line, and for the detection
of the missing parts and functions of the pathomechan-
ism. The selective involvement of skeletal muscles in
TMD heterozygotes remains to be explained, and clar-
ification of the sparing of other muscles may also reveal
clues for therapeutic hypotheses.
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